Editorial
doi: 10.1080/14656566.2020.1819238.
Epub 2020 Sep 21.
What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?
Affiliations
- PMID: 32955945
- DOI: 10.1080/14656566.2020.1819238
Item in Clipboard
Editorial
What are the key considerations when prescribing pharmacotherapy for sickle cell anemia?
Expert Opin Pharmacother.
2021 Jan.
No abstract available
Keywords: L-glutamine; Sickle cell anemia; crizanlizumab; hematopoietic stem cell transplant; hydroxyurea; voxelotor.
Similar articles
-
Two drugs for sickle cell disease.Med Lett Drugs Ther. 2020 Apr 6;62(1595):51-52. Med Lett Drugs Ther. 2020. PMID: 32324178 No abstract available.
-
Hydroxyurea marketed for sickle cell anemia.Am J Health Syst Pharm. 1998 May 1;55(9):875. doi: 10.1093/ajhp/55.9.875. Am J Health Syst Pharm. 1998. PMID: 9588244 No abstract available.
-
Hydroxyurea for sickle cell anemia.N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9. doi: 10.1056/NEJMc080902. N Engl J Med. 2008. PMID: 18596283 No abstract available.
-
Sickle Cell Disease: A Review.JAMA. 2022 Jul 5;328(1):57-68. doi: 10.1001/jama.2022.10233. JAMA. 2022. PMID: 35788790 Review.
-
Hydroxyurea for the treatment of sickle cell anemia.N Engl J Med. 2008 Mar 27;358(13):1362-9. doi: 10.1056/NEJMct0708272. N Engl J Med. 2008. PMID: 18367739 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
